Article
Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression.
Leukemia research - 1 Feb 2003
Stirewalt D L, Appelbaum F R, Willman C L, Zager R A, Banker D E
Abstract excerpt
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase is a rate-limiting enzyme in the mevalonate biochemical pathway and HMG-CoA reductase inhibitors (statins) show toxicity for certain tumors, including acute myeloid leukemia (AML). This toxicity has been attributed to statin inhibition of Ras isoprenylation in tumors like AML where oncogenic ras mutations and/or overexpression are common. We show that...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.